Plain-English translation of NCT05758116 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied , an immunotherapy medication designed to boost the body's immune system to fight cancer cells. The study examined whether giving this medication after radiation therapy (or chemotherapy followed by radiation) could help patients with stage III non-small cell lung cancer who were unable to tolerate the standard combined chemotherapy and radiation treatment.
Most advanced lung cancer patients receive chemotherapy and radiation together, followed by immunotherapy. However, some patients cannot tolerate this intense combination and receive radiation alone or radiation after chemotherapy instead. This trial investigated whether this medication could safely help these patients reduce their risk of cancer returning in distant parts of the body.
Participants in this trial received the medication as an intravenous infusion every 3 weeks for up to 12 months, starting within 42 days after completing their radiation or chemotherapy and radiation treatment. Throughout the study, participants had regular visits for physical exams, blood tests, and imaging scans to monitor how well the medication was working and check for any side effects.
AI-generated summary from trial data · Aug 16, 2026 · Not medical advice
China